Get started
Author

Miguel Ángel Muñoz-Alía

Observed names: Miguel Angel Muñoz-Alía, Miguel Muñoz-Alía, Miguel Á. Muñoz-Alía
Institution: Mayo Clinic
ORCID: 0000-0002-6217-9451
Observed ORCID: 0000-0002-6217-9451
OpenAlex ID: A5003255394
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
2021 · Nir Drayman, Jennifer K. DeMarco, et al. · Science · 273
Designing and Building Oncolytic Viruses
2017 · Justin Maroun, Miguel Muñoz-Alía, et al. · Future Virology · 162
PDF
Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins
2021 · Miguel Ángel Muñoz-Alía, Rebecca A. Nace, et al. · Cell Reports Medicine · 59
PDF
Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients
2020 · Eugene S. Bah, Rebecca A. Nace, et al. · Molecular Cancer Therapeutics · 27
PDF
Antigenic Drift Defines a New D4 Subgenotype of Measles Virus
2017 · Miguel Ángel Muñoz-Alía, Claude P. Muller, et al. · Journal of Virology · 23
PDF
Measles virus genetic evolution throughout an imported epidemic outbreak in a highly vaccinated population
2014 · Miguel Ángel Muñoz-Alía, Rafael Fernández-Muñoz, et al. · Virus Research · 23
MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum
2021 · Miguel Ángel Muñoz-Alía, Rebecca A. Nace, et al. · PLoS Pathogens · 20
PDF
Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins
2019 · Miguel Angel Muñoz-Alía, Stephen J. Russell · Viruses · 20
PDF
Hemagglutinin-specific neutralization of subacute sclerosing panencephalitis viruses
2018 · Miguel Ángel Muñoz-Alía, Claude P. Muller, et al. · PLoS ONE · 17
PDF
Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine
2022 · Kah-Whye Peng, Timothy Carey, et al. · Vaccine · 14
PDF
Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies
2017 · Miguel Angel Muñoz-Alía, José M. Casasnovas, et al. · Virus Research · 14
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination
2019 · Stephen J. Russell, Dusica Babovic-Vuksanovic, et al. · Mayo Clinic Proceedings · 13
PDF
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
2024 · Miguel Á. Muñoz-Alía, Rebecca A. Nace, et al. · mBio · 11
Serotypic Evolution of Measles Is Constrained by Multiple Codominant B-Cell Epitopes on Its Surface Glycoproteins
2019 · Miguel Ángel Muñoz-Alía, Eugene S. Bah, et al. · SSRN Electronic Journal · 2
Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer
2026 · Laura S. Handal, Elad Binshtein, et al. · Cell Reports Medicine
Works count: 15
Citation count: 678
H-index: 12
I10-index: 13
Year
Topic
Type